Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells.
The stocks founds in the One Hot Stock category use stocks that are in long term, short term trends and are early in the buy signal trend. Suggested buy prices are listed with a price “or better”. Or better means anything lower than the buy price listed. (Learn about order types here). This is a confirmation strategy that waits for the stock to make a move then a trader enters the trend at specific prices. In many cases stocks that are in up trends tend to continue the overall trend direction and the prior trend is the path of least resistance. To learn more about trend following as well as reversal strategies you can go here.
